News from Celladon Corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

11 Dec, 2013, 08:30 ET Celladon Corporation Announces Receipt of EMA Scientific Advice for MYDICAR® and Initiation of AGENT-HF Trial

 Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the...


18 Nov, 2013, 16:58 ET Celladon Corporation Announces Oral Presentation at American Heart Association of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure

 Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the...


18 Oct, 2013, 08:30 ET Celladon Corporation Appoints Michael Narachi as Chairman of the Board of Directors

Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field...


11 Oct, 2013, 08:28 ET Celladon Corporation Files Registration Statement for Proposed Initial Public Offering

Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field...


26 Sep, 2013, 11:20 ET Celladon Corporation Announces Publication of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure

 Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the...


10 Sep, 2013, 08:08 ET Celladon Corporation Announces Appointment of Gregg Alton and Graham Cooper to its Board of Directors

 Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the...


30 Jul, 2013, 07:30 ET Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR Reverses Pulmonary Arterial Hypertension (PAH)

Celladon Corporation, a clinical-stage biotechnology company committed to applying its first-mover, leadership position in the field of SERCA...


29 May, 2013, 16:00 ET Celladon Corporation Selected as Winner of Red Herring's "Top 100 North America Tech Startup"

Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases...


08 May, 2013, 09:00 ET Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"

 Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular...


07 May, 2013, 12:00 ET Celladon Corporation is a Finalist for the 2013 Red Herring Top 100 North America Award

 Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular...


29 Mar, 2013, 07:00 ET Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference

Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases,...


23 Jan, 2013, 08:30 ET Celladon Corporation Receives Notice of Allowance from United States Patent and Trademark Office

Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases,...


11 Dec, 2012, 16:30 ET Celladon Corporation Announces First European Patient Dosed in CUPID Phase 2b Trial of MYDICAR® for Advanced Heart Failure

Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases,...


02 Oct, 2012, 06:00 ET Lonza and Celladon Announce Manufacturing Agreement for MYDICAR®

Lonza, a global leader in the field of viral therapy manufacturing, and Celladon Corporation, a biopharmaceutical company focused on the discovery...


19 Sep, 2012, 09:00 ET Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech

Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases,...


29 Aug, 2012, 09:30 ET Celladon Corporation Announces First Patient Dosed in CUPID Phase 2b Trial of MYDICAR® for Advanced Heart Failure

 Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular...


19 Jul, 2012, 09:00 ET Celladon Corporation Receives Patent from United States Patent and Trademark Office

 Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular...


18 Jun, 2012, 09:15 ET Celladon Corporation Receives Notice of Allowance from European Patent Office

 Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular...


15 Feb, 2012, 09:00 ET Celladon Corporation Completes $43 Million Financing to Advance MYDICAR® for the Treatment of Heart Failure

Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases,...


12 Dec, 2011, 10:00 ET Celladon Corporation Receives FDA Fast Track Designation for Its Investigational Agent MYDICAR® for the Treatment of Heart Failure

 Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases,...


23 May, 2011, 10:00 ET Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Reduction in Clinical Events in Patients for 18 Months Compared with Placebo

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today...


23 Mar, 2010, 08:00 ET Celladon Corporation Receives Notice of Allowance by U.S. Patent and Trademark Office for Broad Patent Covering Lead Drug Candidate MYDICAR(R)

Celladon Corp. announced today that the United States Patent and Trademark Office (USPTO) has granted a notice of allowance for a broad patent...


28 May, 2009, 15:15 ET Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting

Phase 1 Data Demonstrate Safety and Evidence of Biological Activity in 9 of 12 Patients; Phase 2 Study Currently Enrolling in 17 Leading U.S....


26 May, 2009, 10:51 ET Celladon Corporation Announces Presentation of First-in-Human Gene Transfer to Treat Heart Failure at the 12th Annual Meeting of the American Society of Gene Therapy

Phase 1/2 Calcium Upregulation by Percutaneous Administration (CUPID) Data Highlight Safety Profile and Biological Effects of SERCA2a Enzyme...


08 Apr, 2009, 08:30 ET The Journal of Cardiac Failure Publishes Results From Celladon Corporation's First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure

Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial) Demonstrated Safety and Biological Effects of...